Front. Cell. Neurosci. Frontiers in Cellular Neuroscience Front. Cell. Neurosci. 1662-5102 Frontiers Media S.A. 10.3389/fncel.2017.00041 Neuroscience Original Research JMV5656, A Novel Derivative of TLQP-21, Triggers the Activation of a Calcium-Dependent Potassium Outward Current in Microglial Cells Rivolta Ilaria 1 * † Binda Anna 1 † Molteni Laura 1 Rizzi Laura 1 Bresciani Elena 1 Possenti Roberta 2 Fehrentz Jean-Alain 3 Verdié Pascal 3 Martinez Jean 3 Omeljaniuk Robert J. 4 Locatelli Vittorio 1 Torsello Antonio 1 1Department of Medicine and Surgery, University of Milano-Bicocca Monza, Italy 2Department of Medicine of Systems, University of Rome “Tor Vergata” Rome, Italy 3CNRS, Institut des Biomolécules Max Mousseron UMR5247, École Nationale Supérieure de Chimie de Montpellier – University of Montpellier Montpellier, France 4Department of Biology, Lakehead University, Thunder Bay ON, Canada

Edited by: Francesco Moccia, University of Pavia, Italy

Reviewed by: Heike Wulff, University of California, Davis, USA; Laura Schrader, Tulane University, USA

*Correspondence: Ilaria Rivolta, ilaria.rivolta@unimib.it

†These authors have contributed equally to this work.

 23 02 2017 2017 11 41 04 10 2016 08 02 2017 Copyright © 2017 Rivolta, Binda, Molteni, Rizzi, Bresciani, Possenti, Fehrentz, Verdié, Martinez, Omeljaniuk, Locatelli and Torsello. 2017 Rivolta, Binda, Molteni, Rizzi, Bresciani, Possenti, Fehrentz, Verdié, Martinez, Omeljaniuk, Locatelli and Torsello

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

TLQP-21 (TLQPPASSRRRHFHHALPPAR) is a multifunctional peptide that is involved in the control of physiological functions, including feeding, reproduction, stress responsiveness, and general homeostasis. Despite the huge interest in TLQP-21 biological activity, very little is known about its intracellular mechanisms of action. In microglial cells, TLQP-21 stimulates increases of intracellular Ca2+ that may activate functions, including proliferation, migration, phagocytosis and production of inflammatory molecules. Our aim was to investigate whether JMV5656 (RRRHFHHALPPAR), a novel short analogue of TLQP-21, stimulates intracellular Ca2+ in the N9 microglia cells, and whether this Ca2+ elevation is coupled with the activation Ca2+-sensitive K+ channels. TLQP-21 and JMV5656 induced a sharp, dose-dependent increment in intracellular calcium. In 77% of cells, JMV5656 also caused an increase in the total outward currents, which was blunted by TEA (tetraethyl ammonium chloride), a non-selective blocker of voltage-dependent and Ca2+-activated potassium (K+) channels. Moreover, the effects of ion channel blockers charybdotoxin and iberiotoxin, suggested that multiple calcium-activated K+ channel types drove the outward current stimulated by JMV5656. Additionally, inhibition of JMV5656-stimulated outward currents by NS6180 (4-[[3-(trifluoromethyl)phenyl]methyl]-2H-1,4 benzothiazin-3(4H)-one) and TRAM-34 (triarylmethane-34), indicated that KCa3.1 channels are involved in this JMV5656 mechanisms of action. In summary, we demonstrate that, in N9 microglia cells, the interaction of JMV5656 with the TLQP-21 receptors induced an increase in intracellular Ca2+, and, following extracellular Ca2+ entry, the opening of KCa3.1 channels.

 TLQP-21 microglia patch clamp Ca2+-activated K+ channels K+ current Università degli Studi di Milano-Bicocca10.13039/501100002954 Introduction

Microglial cells play a pivotal role in the first line of host defense in the central nervous system (Plata-Salaman, 1991). Activated microglia can secrete pro-inflammatory and pro-nociceptive mediators including, but not limited to, tumor necrosis factor (TNF), interleukins 1β, 6, 10, and 18 (IL-1β, IL-6, IL-10, and IL-18), and brain-derived growth factor (BDNF), all of which may be involved in the pathogenesis of chronic and neuropathic pain (Opree and Kress, 2000; Coull et al., 2005; Berta et al., 2014). Neuropathic pain, developing as the result of central or peripheral nervous system damages, is an important clinical problem. Comparison of gene expression profiles in primary sensory neurons following various insults has shown that VGF (non-acronymic) expression was always up-regulated (Maratou et al., 2009). VGF mRNA is expressed throughout the central and the peripheral nervous system. In the rat, the highest levels of VGF mRNA have been measured in the arcuate nucleus of the hypothalamus and in the granular layer of the cerebellum (Snyder and Salton, 1998). VGF is a member of the extended granin family (Bartolomucci et al., 2011), comprising acidic ubiquitous proteins present in secretory cells of the nervous, endocrine and immune systems. It is a propeptide of 617 amino acids in length in mouse and rat, 615 amino acids in human with a highly conserved sequence presenting only variation of 1–2 amino acids in different species. It is processed by PC1/3 and PC2 prohormone convertases to yield several bioactive peptides (Levi et al., 2004). VGF and peptides derived from its processing have been found in dense core vesicles and are released from neuronal and neuroendocrine cells via the regulated secretory pathway (Possenti et al., 1999). TLQP-21 (VGF556-576) is one of most studied among VGF-derived neuropeptides, it is a multifunctional protein which modulates lipolysis, energy balance, gonadotropin, and insulin release, as well as gastroenteric functions and inflammatory pain (Bartolomucci et al., 2006; Severini et al., 2009; Pinilla et al., 2011; Possenti et al., 2012). As far as concerned its action on microglial cells, it has been reported that the activity of C3AR1, a receptor of TLQP-21 that is expressed in microglia, has been implicated in a spectrum of immunomodulatory processes; moreover, TLQP-21 seems to induce p38 MAP kinase phosphorylation and this activation is related to the release of prostaglandins from microglia. Finally, TLQP-21 may lead to production and secretion of some cytokines through gC1qR (Chen et al., 2013; Fairbanks et al., 2014). Although these biological activities have stimulated enormous investigational interest, very little is known about the mechanism of TLQP-21 action at the cellular level. TLQP-21 displays saturable binding to adipocyte membranes and atomic force microscopy demonstrated the expression of a single class of binding sites by CHO cells (Possenti et al., 2012; Cassina et al., 2013). It has been reported that, TLQP-21 induces an increase in intracellular calcium [Ca2+]i levels in ovary, microglial and pituitary cells (Cassina et al., 2013; Chen et al., 2013; Petrocchi Passeri et al., 2013), probably by mobilizing thapsigargin-sensitive stores. In microglial cells, the resident macrophages of the brain, the organization of intracellular Ca2+ signals results from tightly coordinated fluxes of Ca2+ through intracellular and plasmalemmal membranes (Verkhratsky and Parpura, 2014). This implies a very precise coupling of the mechanisms regulating intracellular calcium homeostasis with external stimuli involving the consequent opening of Ca2+-activated potassium (K+) channels. These potassium channels play a central role in several microglial functions, including activation, respiratory burst, proliferation, migration, phagocytosis, and production of inflammatory molecules (Ohana et al., 2009; D’Alessandro et al., 2013). Calcium activated potassium channels are a heterogeneous family and are subgrouped on the basis of conductance as large- (BK or KCa1.1), small- (SK or KCa2.3) and intermediate- (IK or KCa3.1) conductance KCa channels. In principle, they provide a polarizing and potassium extrusion-influence which is integral to regulation of intracellular calcium homeostasis. It has been reported that microglial cells express all the three families of these calcium dependent channels (Kaushal et al., 2007; Schlichter et al., 2010). Interestingly, the elevation in intracellular Ca2+ levels is not sufficient to activate KCa3.1 and KCa2.3 in microglia MLS-9 cells, whereas riluzole, a neuroprotective drug, can activate both channels without inducing significant Ca2+ elevations (Ferreira and Schlichter, 2013).

The purpose of this study was to investigate whether JMV5656 (TLQP-219-21), a novel short analog of TLQP-21, can stimulate an increase in intracellular Ca2+ in the murine microglial cell line N9, and whether this Ca2+ elevation is coupled with the activation of Ca2+-dependent K+ channels.

 Materials and Methods Chemicals

TLQP-21 (TLQPPASSRRRHFHHALPPAR) and JMV5656 (RRRHFHHALPPAR) were synthesized by conventional solid phase peptide synthesis and then purified on a C18 reversed phase column. Each peptide was purified to a purity of at least 95% by high-performance liquid chromatography (chromatograms are shown in Supplementary Figure S1). Unless specified, all other reagents were from Sigma–Aldrich (St Louis, MO, USA).

 Cell Cultures

The murine microglial N9 cells (Corradin et al., 1993) were grown in Iscove’s Modified Dulbecco’s Medium (IMDM; Sigma) supplemented with 5% heat-inactivated fetal bovine serum (FBS), 2 mM L-glutamine, 100 IU/ml penicillin, 100 μg/ml streptomycin (Euroclone, Pero, Italy) and cultured in a controlled environment (at 37°C in humidified incubator with 5% CO2). Stock cells were passaged 2–3 times/week with 1:10 split ratio and used within eight passages.

 Intracellular Ca<sup>2+</sup> (Mobilization Assay)

N9 cells were plated at 20,000 cells/well into black walled, clear bottom 96-well plate (Greiner Bio One, Kremsmünster, Austria) and cultured two days up to 90-100% of confluence. Prior to assay, cells were incubated in darkness with 100 μl of HBSS solution containing 20 mM HEPES, 2.5 mM probenecid and 4.5 μM FLUO-4 NW (Molecular Probes, Eugene, OR, USA) at 37°C and 5% CO2 for 40 min. Probenecid is commonly used to inhibit organic-anion transporters located in the cell membrane to minimize the leakage of the intracellular dye back to the extracellular environment. Fluorescence emissions were measured with the multi-label spectrophotometer VICTOR3 (Perkin Elmer, MA, USA) at 485/535 nm (excitation/emission filters) every 0.5 s for the 20 s preceding and for the 60 s following peptide exposure. TLQP-21 and JMV5656 (1 nM–10 μM) were dissolved in HBSS and injected into the wells by an automated injector system. Fluorescence data have been calculated as (maximum fluorescence–basal fluorescence)/basal fluorescence (ΔF/F), or the percent increase from the last value before stimulation ((Fs/F0)∗100) where F0 is the last basal value before stimulation and Fs is the stimulated value. To assure reproducibility, each experiment has been repeated three times in different days. To control for cell viability and compare the magnitude of the stimulation achieved by TLQP-21 and JMV5656, cells were also stimulated with 10 μM ATP dissolved in HBSS.

 Electrophysiological Recordings

For electrophysiological recordings, N9 cells were plated in p35 dishes (BD Falcon, Sacco, Milano, Italy) 24 h before patch-clamp experiments and cultured in a controlled environment. Just before the current measurements, culture medium was replaced with an extracellular solution previously reported containing 135 mM NaCl, 5.4 mM KCl, 1.8 mM CaCl2, 1 mM MgCl2, 0.4 mM NaH2PO4, 10 mM HEPES, 10 mM glucose (Vecchietti et al., 2006). Whole-cell patch-clamp recordings were performed at room temperature (RT) using pipette pulled to a resistance of 2–5 MΩ (Model P-97 Sutter Instruments, Novato, CA, USA). If not otherwise stated, the pipette intracellular solution contained 122 mM KAsp, 20 mM KCl, 1 mM MgCl2, 1.6 mM CaCl2, 10 mM HEPES, 5 mM EGTA. In this condition the free intracellular Ca2+ concentration was 103,2 nM1. In experiments that required intracellular free calcium concentration of 3 μM, EGTA was lowered to 1.8 and CaCl2 increased to 1.7 mM. In some experiments, EGTA was replaced with 5 mM BAPTA as alternative calcium chelator. In each of these circumstances the osmolarity was adjusted accordingly. Recordings were made with a Multiclamp 700B amplifier, and data were digitized with a Digidata 1440A and pClamp 10.3 software (all from Axon Instruments, Molecular Devices, Sunnyvale, CA, USA). Results were analyzed with Clampfit 10.3 software.

Before studying the effects of JMV5656 on ionic currents in N9 cells, we tested whether the shear stress caused by the superfusion itself could evoke an electrical activity of stretch-activated channels. When stimulated with a step protocol of 400 ms duration, ranging from –120 to +60 mV every 5 s for up to 5 min, from a holding potential of –80 mV, N9 cells did not exhibit differences in the total transmembrane currents upon the superfusion with the extracellular solution (n = 8; data not shown). These experiments confirmed that no stretch-activated channels were activated under these conditions. Therefore, superfused N9 cells could be considered as a suitable model to study the electrophysiological effects of the peptide.

JMV5656 and channel blockers tetraethyl ammonium chloride (TEA), 4-aminopyridine (4-AP), apamin, charybdotoxin (CTX), iberiotoxin (IbTX), triarylmethane-34 (TRAM-34), NS6180 were added to the bath solution. Extracellular solution without calcium contained 135 mM NaCl, 5.4 mM KCl, 1.8 mM EGTA, 1 mM MgCl2, 0.4 mM NaH2PO4, 10 mM HEPES, 10 mM glucose.

Every condition was tested as follow: the extracellular solution containing any given channel blocker was superfused for a minimum of 15 s. After the membrane currents had reached a new equilibrium due to the effect of the perfusion (defined as basal current), we applied the extracellular solution containing the selected channel blocker and 10 μM JMV5656.

 Silencing of K<sub>Ca</sub>3.1 with siRNA

For mRNA silencing we used specific KCa3.1 siRNA duplex (sense: 5′-CGGAGAAACACGUGCACAAdTdT-3′; antisense: 5′-UUGUGCACGUGUUUCUCCGdTdT-3′) (Eurofins Genomics; Vimodrone, Italy). To control for transfection non-specific effects the negative control group was transfected with C3AR1 siRNA (sense: 5′-GUGUACCAGUAUUUGUAUAdTdT-3′; antisense: 5′-UAUACAAAUACUGGUACACdTdT-3′) (Eurofins Genomics). Transfection was performed in a 24-well plate (Euroclone) using DharmaFECT 1 Transfection Reagent (Thermo Scientific, Lafayette, CO, USA) according to the manufacturer’s protocol. Subsequent experiments were performed 24 h after transfection.

 PCR

Total RNA was extracted from N9 cells using EuroGOLD Trifast reagent (Euroclone). For each sample 160 ng of total RNA were transcribed to cDNA using M-MLV Reverse Transcriptase (Invitrogen, Waltham, MA, USA). cDNA was amplified by PCR using GoTaq® G2 DNA Polymerase (Promega, Madison, WI, USA) and the following primers (Sigma): mouse KCa3.1 forward: 5′-CTGAGAGGCAGGCTGTCAATG-3′; mouse KCa3.1 reverse: 5′-ACGTGTTTCTCCGCCTTGTT-3′; GAPDH forward: 5′-GCCATCAACGACCCCTTCATTG-3′; GAPDH reverse: 5′-TCTGTCATGAGGTTGGCTTTCAG-3′.

 Statistical Analysis

Values are expressed as mean ± SE. The statistical significance of differences between groups was evaluated with two-tailed Student’s t-test or, when appropriate, by one-way analysis of variance (ANOVA) followed by or Kruskal-Wallis test. A p-value of less than 0.05 was considered statistically significant and indicated with ∗ in the figures.

 Results JMV5656 Stimulates Intracellular Calcium Mobilization in N9 Cells

We have performed dose-response studies (1 nM–10 μM) to test the activity of TLQP-21 and JMV5656 on N9 cells. Both peptides induced a dose-dependent acute increase in intracellular calcium (Figure 1A). The concentrations in the 0.1–10 μM range evoked a significant increase in intracellular calcium levels in N9 cells, reaching a plateau at the higher doses. Interestingly, JMV5656 was slightly more potent in inducing a calcium response than TLQP-21 (EC50 TLQP-21: 0.96 μM vs. EC50 JMV5656: 0.45 μM). The kinetic of calcium increase after stimulation showed that the peak levels of intracellular calcium increase were reached in 3–4 s, and basal levels restored within 20 s from stimulation (Figure 1B and Supplementary Figure S2). Interestingly, 10 μM JMV5656 stimulated intracellular calcium rise with a kinetic comparable to that of ATP 10 μM, but JMV5656 appeared more effective (Figure 1B): about 37% increase in presence of JMV5656 and 20% in presence of ATP. Since it has been demonstrated that the C-terminal region of TLQP-21 is the sequence retaining the full biological activity (Cero et al., 2014) and likely also the region primarily involved in the binding and activation of its receptor/s, we decided to use 10 μM JMV5656 for the following patch-clamp experiments.

Effect of TLQP-21 and JMV5656 on calcium mobilization in N9 cells. (A) Dose-response study of intracellular calcium stimulation by TLQP-21 and JMV5656. Intracellular calcium concentrations were measured in N9 cells using the fluorophore Fluo-4 NW as indicated in the Section “Materials and Methods”. Data represent the peak values of intracellular calcium levels achieved for each concentration of the stimuli, and were calculated as ΔF/F, meaning (maximum fluorescence–basal fluorescence)/basal fluorescence. The 0 concentration is the ΔF/F measured in cells stimulated with the vehicle only; the small increase in fluorescence is likely induced by the injection procedure itself. Each point is the mean ± SE of 18 measurements obtained in three independent experiments. (B) A representative time-course of intracellular calcium stimulation by JMV5656. Data were calculated as Fluorescence %, meaning (fluorescence after stimulation/last basal fluorescence before stimulation)∗100. The effects of 10 μM ATP is shown for comparison. Arrows indicate injection of the stimuli. Fluorescence emissions were measured at 485/535 nm (excitation/emission filters) every 0.5 s for the 20 s preceding and for the 60 s following peptide as indicated in the Section “Materials and Methods”.

 JMV5656 Effects on N9 Cells Transmembrane Currents

The perfusion of 10 μM JMV5656 induced an increase of about threefold in the total outward currents in 79% of cells tested (41 cells out of 52). The total outward currents increased to 33.3 ± 7.8 pA/pF, from a value of 10.9 ± 2.7 pA/pF measured at baseline condition at 60 mV (Figures 2A–C). Moreover, the value of the reversal potential hyperpolarized from -19.6 ± 3.3 mV to –35.7 ± 8.3 mV (p < 0.05) after 40 s of the peptide perfusion (Figure 2C), time in which the increase of the outward currents reached a plateau, before returning to baseline (Supplementary Figure S3). This effect was concentration-dependent (Figure 2D).

Effects of JMV5656 superfusion on N9 cells. (A,B) Representative families of currents traces acquired from N9 cells through a step protocol from –120 to +60 mV applied form a holding potential of -80 mV in control conditions (A), and every five seconds from the opening of the perfusion with JMV5656 up to 40 s (B). (C) Current/voltage relationship in the presence of JMV5656. In the plot, the currents amplitude is presented as normalized relative to the baseline current for each cell. Normalized currents measured were 0.92 ± 0.09 and 3.6 ± 0.5 after 40 s perfusion with extracellular solution and 10 μM JMV5656 (n = 25), respectively. Data are presented as mean ± SE. (D) Bars graph showing the dose-response effect of the perfusion of JMV5656 measured at +60 mV (n = 8, 8 and 25 for 0.1 μM, 1 μM, and 10 μM, respectively. ∗p < 0.05 vs. 0.1 μM JMV5656).

 JMV5656 Activated Potassium Currents in N9 Cells

The results obtained, in particular the hyperpolarization of the reversal potential, suggested that the peptide could activate a potassium current. Consequently, TEA, a non-selective blocker of voltage-dependent and Ca2+-activated potassium (K+) channels, was added to the extracellular solution at 10 mM in order to determine whether JMV5656 could influence K+ currents. First, we recorded current traces in N9 cells perfused with the extracellular solution containing 10 mM TEA alone (Figure 3A). When TEA was subsequently administered in combination with 10 μM JMV5656, the outer membrane currents increased by 2.00 ± 0.3-fold (from 14.3 + 6.4 pA/pF in TEA alone to 26.5 ± 8.8 pA/pF in TEA+JMV5656, values measured at 60 mV; p < 0.05) (Figures 3B,C). The ability of TEA to attenuate JMV5656-stimulated outward currents so significantly suggested an involvement of K+ channels activation in the N9 cells response to JMV5656 stimulation. In order to discriminate whether voltage-gated K+ channels were involved in the response, we perfused the cells with 5 mM 4-AP, a broad-spectrum blocker of voltage-gated K+ channel (Figure 3D). Interestingly, 4-AP did not inhibit the effect of JMV5656, which was still capable to induce a 3.0 ± 1.1-fold increase of outward currents (Figures 3E,F).

Effects of TEA and 4-AP on the superfusion of JMV5656 in N9 cells. (A,B) Representative families of current traces recorded in N9 cells perfused with extracellular solution containing TEA (A) and after 40 s of perfusion with TEA plus JMV5656 peptide (B). (C) Current/voltage relationship at different time points from the opening of the perfusion of extracellular solution containing TEA plus JMV5656. Currents are normalized to the value of the baseline current recorded at +60 mV. Empty symbols indicates the presence of TEA, filled symbols the presence of TEA and JMV5656. (D,E) Representative families of current traces recorded in N9 cells perfused with extracellular solution containing 4-AP (D) and after 40 s of perfusion with 4-AP plus JMV5656 peptide (E). (F) Current/voltage relationship at different time points from the opening of the perfusion of extracellular solution containing 4-AP plus JMV5656. Currents are normalized to the value of the baseline current recorded at +60 mV. Empty symbols indicate the presence of 4-AP, filled symbols the presence of 4-AP and JMV5656. Data are expressed as mean ± SE. ∗p < 0.05 vs respective baseline values (n = 5 in all conditions).

 JMV5656 Activates Calcium-Dependent Potassium Channels

Since JMV5656 dose-dependently boosted a significant increase of intracellular calcium levels in N9 cells (Figure 1), we focused our attention on the possible involvement of calcium-activated potassium channels in its mechanism of action. To ascertain whether KCa2 channels were engaged in this JMV5656 activity, N9 cells were perfused with apamin, a drug that blocks KCa2.2 at 200 pM and KCa2.1 and KCa2.3 at nM concentrations (Wulff et al., 2007). Interestingly, 100 nM apamin could not prevent the rise of total outward currents stimulated by JMV5656 perfusion: when measured at +60 mV, the current amplitude increased about 2.5 ± 0.5-fold (p < 0.05) from 18.9 ± 6.7 pA/pF in the apamin group to 45.8 ± 10 pA/pF in the apamin + JMV5656 (Figure 4). These data suggested that KCa2 channels were not primarily involved in JMV5656 mechanism of action. Application of charybdotoxin (CTX, 100 nM), a KCa1.1, KCa3.1, and voltage-gated Kv1.3 channel’s blocker (Gao and Garcia, 2003), instead, yielded a 1.25 ± 0.13-fold higher variation in the outer currents compared to controls (Figure 4), suggesting that KCa1.1 or KCa3.1 channels could be associated to the JMV5656 mechanism of action. We ruled out the involvement of Kv1.3 channels since they are also inhibited by TEA and 4-AP (Comes et al., 2013). It is worthy to remember that KCa3.1 channels are insensitive to TEA, which instead, blocks KCa1.1 (Tricarico et al., 2013). When N9 cells were perfused with an extracellular solution containing 100 nM iberiotoxin (IbTX) that selectively inhibits KCa1.1 channels (Gao and Garcia, 2003), JMV5656 was still capable of stimulating a partial increase of the total outward currents (2.2 ± 0.5-fold), suggesting that KCa1.1 channels could be involved in the JMV5656 activated pathway (Figure 4).

Effect of the perfusion of extracellular solutions containing JMV5656 plus potassium channels blockers. Data are expressed as current amplitude recorded at +60 mV after 40 s of perfusion and normalized to the value of the baseline current recorded at the same voltage membrane. Data are expressed as mean ± SE (n = at least eight cells for each condition) ∗p < 0.05 vs. JMV5656

Thus, these results suggested that (i) JMV5656-stimulated potassium outward current is not driven by a single type of calcium activated K+ channel, and (ii) that both KCa1.1 and KCa3.1 might be recruited.

 JMV5656 Could Be Responsible for K<sub>Ca</sub>3.1 Channels Activation

NS6180, which has been recently identified as a novel KCa3.1 channel’s inhibitor (Strøbæk et al., 2013), was used to investigate the potential involvement of KCa3.1 channels in the effects of JMV5656 perfusion. When NS6180 at a concentration of 250 nM was added to the superfusion solution containing the peptide, the outward current declined of the 94,6 ± 4.6 % (n = 6, data not shown), while no effect of the drug was visible on the baseline currents (Supplementary Figure S4).

To further characterize the involvement of KCa3.1 channels in the JMV5656 action, we measured the effects of TRAM-34, one of the most recognized selective blocker of KCa3.1 channels (Wulff et al., 2000). In this instance, N9 cells were (i) first superfused either with the extracellular solution alone (Figure 5A) or with the extracellular solution containing 10 μM JMV5656 for 25 s (Figure 5B), an interval of time sufficient for JMV5656 effects to become significant (the outer current increased from 15.0 ± 4.2 pA/pF to 37.5 ± 10.1 pA/pF; p < 0.05), and (ii) thereafter switched to a solution containing JMV5656 and 2 μM TRAM-34 (Figure 5C). The current amplitude decreased significantly (19.0 ± 8.6 pA/pF) (Figures 5D,E).

Effects of TRAM-34 on N9 cells superfused with JMV5656. (A–C) Representative families of current traces recorded in N9 cells before (A) and after 25 s (B) of perfusion with JMV5656 peptide and after 40 s of perfusion with JMV5656 peptide plus TRAM-34 (C). (D) Current/voltage relationship of baseline (empty symbols), 25 s of JMV5656 perfusion (filled circles) and 40 s of TRAM-34 plus JMV5656 perfusion (filled triangles). Currents are normalized on the value of baseline current recorded at +60 mV (n = 19). (E) Bar graph representing normalized current after 40 s of perfusion. Data have been obtained in three independent experiments. Data are expressed as mean ± SE.

Extracellular calcium is crucial for the activation of KCa3.1 channels (Ferreira and Schlichter, 2013) and indeed our data indicate that JMV5656 failed to activate the outward currents when the extracellular environment was devoid of Ca2+ (Figures 6A–D). In fact, the outward currents density measured at +60 mV was similar before (11.2 ± 4.5 pA/pF) and after JMV5656 superfusion (14.4 ± 7.1 pA/pF). Accordingly, when extracellular calcium is chelated by the presence of EGTA 1 mM, also the mobilization of the intracellular calcium is very low and did not significantly differed from the control condition, blunting the effect of JMV5656 (Figure 6E).

Extracellular and intracellular Ca2+ dependence of JMV5656 effect on KCa3.1 channels. (A,B) Representative families of currents traces recorded in N9 cells perfused with the regular extracellular solution (A) and after 40 s of extracellular solution containing 0 mM Ca2+ and JMV5656 (B) in a condition of intracellular free calcium concentration of 100 nM. (C) Current/voltage relationship during perfusion with the extracellular solution (baseline, empty symbols) and perfusion containing JMV5656 (filled symbols) but lacking of Ca2+. (D) Normalized current amplitude recorded at +60 mV after 40 s of perfusion with extracellular solution (n = 11), JMV5656 (n = 9), JMV5656 without extracellular Ca2+ (n = 15). (E) Cytosolic calcium mobilization, expressed as variation in fluorescence intensity, obtained in N9 cells stimulated with the vehicle only (HBSS), with JMV5656 and with JMV5656 in presence of 1 mM EGTA to chelate the extracellular calcium. (F) Current/voltage relationship obtained in presence of JMV5656 in the extracellular solution and BAPTA 5 mM in the intracellular one (n = 5). (G) Current/voltage relationship obtained in presence of JMV5656 in the extracellular solution and 3 μM free intracellular calcium (n = 16); recording were made at selected time points (5, 15, 25, and 40 s). ∗p < 0.05 vs control group. All data have been obtained in three independent experiments.

To further confirm a substantial involvement of KCa3.1 beside KCa1.1 in the peptide response, we reasoned on the potassium channel calcium sensitivity. Outward currents were recorded in presence of 3 μM free intracellular calcium concentration, a condition at which KCa3.1 is fully activated, while KCa1.1 is not. In this scenario, we observed that the effect of JMV5656 was gone, despite the reversal potential of the total transmembrane currents was shifted in the hyperpolarized direction as it appeared after the activation of the outward current by the peptide (Figure 6F). Finally, in presence of BAPTA as intracellular calcium chelator, JMV5656 failed to activate KCa currents (Figure 6G).

 Inhibition of K<sub>Ca</sub>3.1 Channels mRNA Levels in N9 Cells

To confirm the role of KCa3.1 channels in JMV5656 effects, we used specific siRNA to reduce the mRNA levels of this channel in N9 cells. Transfection of KCa3.1 siRNA duplex significantly reduced (p < 0.05) KCa3.1 mRNA levels (Figure 7A). Moreover, after silencing KCa3.1 channels, there was a significant decrease in the number of cells responsive to JMV5656 stimulation in terms of activation of outward currents (Figure 7B). Cells responding to JMV5656 decreased from 79% in control group to 33% in the siRNA group. Among the responsive cells, the outward current increase was confirmed to be of about 3.2 ± 0.7-fold. These results support the hypothesis of a KCa3.1 involvement in the JMV5656-induced effect.

Effect of KCa3.1 siRNA on N9 cells superfused with JMV5656. (A) Bars graph showing that KCa3.1 mRNA levels were significantly reduced after transfection with 50 nM siRNA for 24 h. The inset shows representative PCR: lane 1 N9; lane 2 N9 transfected with siRNA negative control; lane 3–4 N9 transfected with KCa3.1 siRNA. (B) Bar graph showing that in presence KCa3.1 siRNA the percentage of N9 cells responsive to JMV5656 was reduced from 79% (control cells) to 33% (siRNA transfected cells) (n = 9). Data are the mean ± SE of results obtained in three independent experiments. ∗p < 0.05 vs control group.

 Discussion

The diversity of known biological- and medically relevant activities for TLQP-21(VGF556-576) is expanding rapidly. Accordingly, this study investigates modulation of selected transmembranal ionic currents as an element of TLQP-21 intracellular signaling in the microglial cell model. TLQP-21 was initially immunopurified from rat brain and further immunolocalized in gastric tissue as well as in adrenergic neurons (Hahm et al., 1999; Bartolomucci et al., 2006; Brancia et al., 2010). The known biological effects of TLQP-21 are diverse. Although VGF knockout mice are smaller and thinner compared to their wild type littermates (Salton et al., 2000), TLPQ-21 was shown to induce anorexic effects, to activate lipolysis and modulate inflammatory pain, and to blunt obesity induced by diet (Bartolomucci et al., 2006, 2009; Rizzi et al., 2008). The biological effects of TLQP-21 are receiving increasing attention, but the specific receptor(s), which mediate its effects are still a matter of considerable debate (Chen et al., 2013; Hannedouche et al., 2013); moreover, there is little information about the TLQP-21 mechanism of action. Our results demonstrate that TLQP-21 like JMV5656 (i.e., TLQP-219-21) increased intracellular calcium levels in N9 microglia cells. We have decided to perform our experiments using the N9 immortalized mouse microglia cells, which were previously demonstrated to be a suitable model for studies on microglia (Bureau et al., 2008; Wang et al., 2008) and might be a valuable alternative to primary mouse microglia culture for use in pharmacological and toxicological investigations. Microglial cells are known to be the immune effector cells in the brain (Streit, 2004) and the first line of defense against pathogens and acute or chronic brain injuries. Reportedly, neurodegenerative diseases, stroke and tumor invasion, induce an activation of microglia cells that enclose damaged and dead cells and remove cellular debris from the area, functioning as phagocytic macrophages. Microglial cells are responsible for the release of a variety of pro-inflammatory mediators such as cytokines, reactive oxygen species, complement factors, neurotoxic secretory products, free radical species, and nitric oxide (NO) which could contribute to both neuronal dysfunction and cell death (Griffin et al., 1998).

In N9 microglia cells, we have found that JMV5656 possesses the same biological activity with slightly higher potency than TLQP-21 in its ability to enhance [Ca2+]i. These results are in agreement with the study of Cero et al. (Cero et al., 2014) who demonstrated that the hot spots for the biological activity of the TLQP-21 are in its C-terminus and that the retention of its last thirteen amino acids is sufficient to have a peptide with a comparable biological activity. In terms of quantification and how high JMV5656 raised intracellular Ca2+, we could speculate from what is known from the literature. In N13, a cell line immortalized from primary mice microglial cell and very similar to N9, the basal intracellular calcium concentration was found to be about 150–200 nM (Ferrari et al., 1996). Since when we stimulated with 10 μM JMV5656 the increase in calcium level was of about 40%, we expect that the free calcium concentration in this condition might be about 210–280 nM.

In microglia, the elevation of cytosolic calcium levels is necessary for cytokine induction (Hoffmann et al., 2003) and cellular activation. Moreover, previous studies reported a tight association between intracellular calcium-dependent signaling and Ca2+-dependent potassium channels activity (Stocker, 2004). For example, Ca2+-dependent potassium channels, such as KCa1.1, KCa3.1, and KCa2.3 seemed to be linked in particular to microglial activation processes (Bordey and Spencer, 2003; Schlichter et al., 2010).

Indeed, our data show that JMV5656 was responsible for the activation of an outward K+ current which is calcium dependent as revealed by charybdotoxin and iberiotoxin sensitivity. We speculate that the general role of these potassium channels is to provide a membrane polarizing influence (viz. potassium efflux) which offsets the depolarizing action of calcium elevation, and indirectly to maintain the driving force for optimal calcium increase in the cytosol. Moreover, the calcium-activated potassium channels help to regulate the volume of microglial cells during migration. The changes of shape and volume seem to be a prerequisite for cell migration. It is possible that in microglia, calcium-activated potassium currents cause wrinkling of the cell body, as proposed by Schwab (2001). This change of shape can promote the migration, facilitating the retraction of the rear part of the cell.

Interestingly, our results suggest that JMV5656 mainly, even not specifically, activates KCa3.1 currents. In fact, while apamin, a blocker of KCa2 when used in the nanomolar range, was not able to prevent the increase in outward K+ currents, charybdotoxin that inhibits KCa1.1, KCa3.1 channels (Gao and Garcia, 2003) and iberiotoxin, that inhibits KCa1.1 (Salton et al., 2000), were capable of blunting (the former in a complete way, the second partially) the ability of JMV5656 to activate outward K+ currents. Further details were gained by the use of NS6180 and TRAM-34, which allowed proving that mostly the intermediate-conductance Ca2+-activated K+ channels KCa3.1 were involved in the effects of JMV5656 perfusion. Moreover, KCa3.1 activation depends on the presence of extracellular calcium and this channel activity is not induced by several stimuli that release Ca2+ from intracellular stores but which do not stimulate Ca2+ influx (Cruse et al., 2006), and our results are in line with this knowledge. To strengthen the hypothesis of a prevalent contribution of KCa3.1 channels than KCa1.1 in the peptide response, we reasoned on their respective calcium sensitivity. The typical intracellular solution for whole cell measurements allowed us to have an free calcium concentration of 100 nM, that is below the threshold of the calcium-dependent activation of both KCa3.1 and KCa1.1. The former channel relies on the use of calmodulin as Ca2+ sensor, thus shows an intrinsically high affinity for calcium, while for the second, the calcium bowl requires higher calcium concentration to activate the protein. Considering that JMV5656 induced a 40% increase of free [Ca2+]i (Figure 1B), the intracellular calcium level reached after the peptide perfusion was compatible with the activation of KCa3.1 (Joiner et al., 1997; Ferreira and Schlichter, 2013) but not of the KCa1.1 (Rothberga and Magleby, 2000). Furthermore, a [Ca2+]i of 3 μM, fully activates KCa3.1, while the full activation of KCa1.1 required 10 μM [Ca2+]i. Indeed, in 3 μM free calcium, JMV5656 failed to activated a large outward current, consistent with the prevalence of KCa3.1 already activated (hypothesis confirmed also by the hyperpolarization of the Vrev already significant before the peptide perfusion). Finally, the partial silencing of the mRNA for KCa3.1 reduced the number of cells responsive to JMV5656.

It is interesting at this point at least TO speculate what the sources for the JMV565 triggered Ca2+ influx could be. The data obtained in presence of BAPTA in the intracellular solution suggested a coupling between the calcium source and the calcium sensor (KCa) in the nanometers range (Fakler and Adelman, 2008). In fact, in accordance with this interpretation, BAPTA, with its 150 times faster calcium binding rate compared to EGTA, thus more effective in preventing calcium diffusion, interfered with the outcome of JMV5656. Extracellular calcium was necessary to activate JMV5656 response, thus one may think that calcium channels on the plasma membrane may be the primum movens required to trigger the KCa activation which may be found in their very close proximity. In microglial cells, L-type calcium channels are indeed present and preliminary data (not shown) from our lab indicated that nifedipine (10 μM) blunted the increase of the outward current JMV5656-mediated (only 40% respect to the baseline), suggesting a potential involvement of L-type calcium channel in the activation of the KCa. But, since the outward current required at least 25 s of peptide perfusion to manifest, it would be hard to think at a direct effect of the peptide on the L-type calcium channel opening, but quite reasonably this delay is more consistent with the generation of second messengers that may affect the Ca2+ channel activity.

Thus, we suggest that JMV5656 acting on its receptor(s) generates an increase in cytosolic calcium that, together with the depolarization, may open calcium channels (L-type?) found on the plasma membrane of the N9 cells. The calcium ions entered through this route might favor the activation of an outward potassium current mediated mainly by KCa3.1 found in their nanometers range proximity.

The ability of JMV5656 (and TLQP-21) to stimulate microglia cells is an interesting finding that might help for the development of antagonist as new therapeutic tools for the care and the treatment of neuropathic pain. In fact, it has been reported that injection of TLQP-21 into the hind paw of mice resulted in hypersensitivity in both control conditions and in a model of inflammatory pain (Rizzi et al., 2008). In the dorsal horn, stimulation of microglia by TLQP-21 could lead to production and secretion of cytokines responsible for the activation of sensory neurons. Recently the gC1qR and C3AR1 complement protein receptors, have been proposed to be involved in the TLQP-21 mechanism of action (Chen et al., 2013; Hannedouche et al., 2013).

 Conclusion

By measuring the outward K+ currents, we were able to demonstrate that by interacting with its cellular receptors, JMV5656, a derivative of TLQP-21, was capable to stimulate increase in intracellular calcium, which activated, even not in exclusively manner, KCa3.1 channels in N9 microglia cells. The opening of KCa3.1 channels is important for the hyperpolarization of the plasma membrane which allows maintaining the driving force for Ca2+ to entry from the extracellular environment and an optimal replenishment of intracellular Ca2+ stores.

 Author Contributions

IR, AT: Substantial contribution to the design of the work, interpretation of the data, drafting the work, final approval of the version to be published, agreement to be accountable for all the aspects of the work. AB, LM, LR, EB: Substantial contribution to the acquisition, analysis of the work, final approval of the version to be published, agreement to be accountable for all the aspects of the work. RP, RO, J-AF, PV, JM, VL: Substantial contribution to the interpretation of the data, final approval of the version to be published, agreement to be accountable for all the aspects of the work.

 Conflict of Interest Statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Funding. This work was supported by Fondo di Ateneo per la Ricerca of the University of Milano-Bicocca (FAR to IR, AT, and VL).

 Supplementary Material

The Supplementary Material for this article can be found online at: http://journal.frontiersin.org/article/10.3389/fncel.2017.00041/full#supplementary-material

 References Bartolomucci A. Bresciani E. Bulgarelli I. Rigamonti A. E. Pascucci T. Levi A. (2009). Chronic intracerebroventricular injection of TLQP-21 prevents high fat diet induced weight gain in fast weight-gaining mice. Genes Nutr. 4 49–57. 10.1007/s12263-009-0110-0 Bartolomucci A. La Corte G. Possenti R. Locatelli V. Rigamonti A. E. Torsello A. (2006). TLQP-21, a VGF-derived peptide, increases energy expenditure and prevents the early phase of diet-induced obesity. Proc. Natl. Acad. Sci. U.S.A. 103 14584–14589. 10.1073/pnas.0606102103 Bartolomucci A. Possenti R. Mahata S. K. Fischer-Colbrie R. Loh Y. P. Salton S. R. (2011). The extended granin family: structure, function, and biomedical implications. Endocr. Rev. 32 755–797. 10.1210/er.2010-0027 Berta T. Park C. K. Xu Z. Z. Xie R. G. Liu T. Lu N. (2014). Extracellular caspase-6 drives murine inflammatory pain via microglial TNF-alpha secretion. J. Clin. Invest. 124 1173–1186. 10.1172/JCI72230 Bordey A. Spencer D. D. (2003). Chemokine modulation of high-conductance Ca(2+)-sensitive K(+) currents in microglia from human hippocampi. Eur. J. Neurosci. 18 2893–2898. 10.1111/j.1460-9568.2003.03021.x Brancia C. Cocco C. D’Amato F. Noli B. Sanna F. Possenti R. (2010). Selective expression of TLQP-21 and other VGF peptides in gastric neuroendocrine cells and modulation by feeding. J. Endocrinol. 207 329–341. 10.1677/JOE-10-0189 Bureau G. Longpré F. Martinoli M. G. (2008). Resveratrol and quercetin, two natural polyphenols, reduce apoptotic neuronal cell death induced by neuroinflammation. J. Neurosci. Res. 86 403–410. 10.1002/jnr.21503 Cassina V. Torsello A. Tempestini A. Salerno D. Brogioli D. Tamiazzo L. (2013). Biophysical characterization of a binding site for TLQP-21, a naturally occurring peptide which induces resistance to obesity. Biochim. Biophys. Acta 1828 455–460. 10.1016/j.bbamem.2012.10.023 Cero C. Vostrikov V. V. Verardi R. Severini C. Gopinath T. Braun P. D. (2014). The TLQP-21 peptide activates the G-protein-coupled receptor C3aR1 via a folding-upon-binding mechanism. Structure 22 1744–1753. 10.1016/j.str.2014.10.001 Chen Y. C. Pristera A. Ayub M. Swanwick R. S. Karu K. Hamada Y. (2013). Identification of a receptor for neuropeptide VGF and its role in neuropathic pain. J. Biol. Chem. 288 34638–34646. 10.1074/jbc.M113.510917 Comes N. Bielanska J. Vallejo-Gracia A. Serrano-Albarrás A. Marruecos L. Gómez D. (2013). The voltage-dependent K+ channels Kv1.3 and Kv1.5 in human cancer. Front. Physiol. 4:283. 10.3389/fphys.2013.00283 Corradin S. B. Mauel J. Donini S. D. Quattrocchi E. Ricciardi-Castagnoli P. (1993). Inducible nitric oxide synthase activity of cloned murine microglial cells. Glia 7 255–262. 10.1002/glia.440070309 Coull J. A. Beggs S. Boudreau D. Boivin D. Tsuda M. Inoue K. (2005). BDNF from microglia causes the shift in neuronal anion gradient underlying neuropathic pain. Nature 438 1017–1021. 10.1038/nature04223 Cruse G. Duffy S. M. Brightling C. E. Bradding P. (2006). Functional KCa3.1 K+ channels are required for human lung mast cell migration. Thorax 61 880–885. 10.1136/thx.2006.060319 D’Alessandro G. Catalano M. Sciaccaluga M. Chece G. Cipriani R. Rosito M. (2013). KCa3.1 channels are involved in the infiltrative behavior of glioblastoma in vivo. Cell Death Dis. 4:e773. 10.1038/cddis.2013.279 Fairbanks C. A. Peterson C. D. Speltz R. H. Riedl M. S. Kitto K. F. Dykstra J. A. (2014). The VGF-derived peptide TLQP-21 contributes to inflammatory and nerve injury-induced hypersensitivity. Pain 155 1229–1237. 10.1016/j.pain.2014.03.012 Fakler B. Adelman J. P. (2008). Control of KCa channels by calcium nano/microdomains. Neuron 59 873–881. 10.1016/j.neuron.2008.09.001 Ferrari D. Villalba M. Chiozzi P. Falzoni S. Ricciardi-Castagnoli P. Di Virgilio F. (1996). Mouse microglial cells express a plasma membrane pore gated by extracellular ATP. J. Immunol. 156k1531–1539. Ferreira R. Schlichter L. C. (2013). Selective activation of KCa3.1 and CRAC channels by P2Y2 receptors promotes Ca(2+) signaling, store refilling and migration of rat microglial cells. PLoS ONE. 8:e62345. 10.1371/journal.pone.0062345 Gao Y. D. Garcia M. L. (2003). Interaction of agitoxin2, charybdotoxin, and iberiotoxin with potassium channels: selectivity between voltage-gated and Maxi-K channels. Proteins 52 146–154. 10.1002/prot.10341 Griffin W. S. Sheng J. G. Royston M. C. Gentleman S. M. McKenzie J. E. Graham D. I. (1998). Glial-neuronal interactions in Alzheimer’s disease: the potential role of a ‘cytokine cycle’ in disease progression. Brain Pathol. 8 65–72. 10.1111/j.1750-3639.1998.tb00136.x Hahm S. Mizuno T. M. Wu T. J. Wisor J. P. Priest C. A. Kozak C. A. (1999). Targeted deletion of the Vgf gene indicates that the encoded secretory peptide precursor plays a novel role in the regulation of energy balance. Neuron 23 537–548. 10.1016/S0896-6273(00)80806-5 Hannedouche S. Beck V. Leighton-Davies J. Beibel M. Roma G. Oakeley E. J. (2013). Identification of the C3a Receptor (C3AR1) as the Target of the VGF-derived Peptide TLQP-21 in Rodent Cells. J. Biol. Chem. 288 27434–27443. 10.1074/jbc.M113.497214 Hoffmann A. Kann O. Ohlemeyer C. Hanisch U. K. Kettenmann H. (2003). Elevation of basal intracellular calcium as a central element in the activation of brain macrophages (microglia): suppression of receptor-evoked calcium signaling and control of release function. J. Neurosci. 23 4410–4419. Joiner W. J. Wang L. Y. Tang M. D. Kaczmarek L. K. (1997). hSK4, a member of a novel subfamily of calcium-activated potassium channels. Proc. Natl. Acad. Sci. U.S.A. 94 11013–11018. 10.1073/pnas.94.20.11013 Kaushal V. Koeberle P. D. Wang Y. Schlichte L. C. (2007). The Ca2+-activated K+ channel KCNN4/KCa3.1 contributes to microglia activation and nitric oxide-dependent neurodegeneration. J. Neurosci. 27 234–244. 10.1523/JNEUROSCI.3593-06.2007 Levi A. Ferri G. L. Watson E. Possenti R. Salton S. R. (2004). Processing, distribution, and function of VGF, a neuronal and endocrine peptide precursor. Cell Mol. Neurobiol 24 517–533. 10.1023/B:CEMN.0000023627.79947.22 Maratou K. Wallace V. C. Hasnie F. S. Okuse K. Hosseini R. Jina N. (2009). Comparison of dorsal root ganglion gene expression in rat models of traumatic and HIV-associated neuropathic pain. Eur. J. Pain 13 387–398. 10.1016/j.ejpain.2008.05.011 Ohana L. Newell E. W. Stanley E. F. Schlichter L. C. (2009). The Ca2+ release-activated Ca2+ current (I(CRAC)) mediates store-operated Ca2+ entry in rat microglia. Channels 3 129–139. 10.4161/chan.3.2.8609 Opree A. Kress M. (2000). Involvement of the proinflammatory cytokines tumor necrosis factor-alpha, IL-1 beta, and IL-6 but not IL-8 in the development of heat hyperalgesia: effects on heat-evoked calcitonin gene-related peptide release from rat skin. J. Neurosci. 20 6289–6293. Petrocchi Passeri P. Biondini L. Mongiardi M. P. Mordini N. Quaresima S. Frank C. (2013). Neuropeptide TLQP-21, a VGF internal fragment, modulates hormonal gene expression and secretion in GH3 cell line. Neuroendocrinology 97 212–224. 10.1159/000339855 Pinilla L. Pineda R. Gaytan F. Romero M. Garcia-Galiano D. Sanchez-Garrido M. A. (2011). Characterization of the reproductive effects of the anorexigenic VGF-derived peptide TLQP-21: in vivo and in vitro studies in male rats. Am. J. Physiol. Endocrinol. Metab. 300 E837–E847. 10.1152/ajpendo.00598.2010 Plata-Salaman C. R. (1991). Immunoregulators in the nervous system. Neurosci. Biobehav. Rev. 15 185–215. 10.1016/S0149-7634(05)80001-6 Possenti R. Muccioli G. Petrocchi P. Cero C. Cabassi A. Vulchanova L. (2012). Characterization of a novel peripheral pro-lipolytic mechanism in mice: role of VGF-derived peptide TLQP-21. Biochem. J. 441 511–522. 10.1042/BJ20111165 Possenti R. Rinaldi A. M. Ferri G. L. Borboni P. Trani E. Levi A. (1999). Expression, processing, and secretion of the neuroendocrine VGF peptides by INS-1 cells. Endocrinology 140 3727–3735. 10.1210/en.140.8.3727 Rizzi R. Bartolomucci A. Moles A. D’Amato F. Sacerdote P. Levi A. (2008). The VGF-derived peptide TLQP-21: a new modulatory peptide for inflammatory pain. Neurosci. Lett. 441 129–133. 10.1016/j.neulet.2008.06.018 Rothberga B. S. Magleby K. L. (2000). Voltage and Ca2+ activation of single large-conductance Ca2+-activated K+ channels described by a two-tiered allosteric gating mechanism. J. Gen. Physiol. 116 75–100. 10.1085/jgp.116.1.75 Salton S. R. Ferri G. L. Hahm S. Snyder S. E. Wilson A. J. Possenti R. (2000). VGF: a novel role for this neuronal and neuroendocrine polypeptide in the regulation of energy balance. Front. Neuroendocrinol. 21:199–219. 10.1006/frne.2000.0199 Schlichter L. C. Kaushal V. Moxon-Emre I. Sivagnanam V. Vincent C. (2010). The Ca2+ activated SK3 channel is expressed in microglia in the rat striatum and contributes to microglia-mediated neurotoxicity in vitro. J. Neuroinflammation 7:4. 10.1186/1742-2094-7-4 Schwab A. (2001). Function, and spatial distribution of ion channels, and transporters in cell migration. Am. J. Physiol. Renal Physiol. 280 F739–F747. Severini C. La Corte G. Improta G. Broccardo M. Agostini S. Petrella C. (2009). In vitro and in vivo pharmacological role of TLQP-21, a VGF-derived peptide, in the regulation of rat gastric motor functions. Br. J. Pharmacol. 157 984–993. 10.1111/j.1476-5381.2009.00192.x Snyder S. E. Salton S. R. (1998). Expression of VGF mRNA in the adult rat central nervous system. J. Comp. Neurol. 27 91–105. 10.1002/(SICI)1096-9861(19980427)394:1<91::AID-CNE7>3.0.CO;2-C Stocker M. (2004). Ca(2+)-activated K+ channels: molecular determinants and function of the SK family. Nat. Rev. Neurosci. 5 758–770. 10.1038/nrn1516 Streit W. J. (2004). Microglia and Alzheimer’s disease pathogenesis. J. Neurosci. Res. 77 1–8. 10.1002/jnr.20093 Strøbæk D. Brown D. T. Jenkins D. P. Chen Y. J. Coleman N. Ando Y. (2013). NS6180, a new K(Ca) 3.1 channel inhibitor prevents T-cell activation and inflammation in a rat model of inflammatory bowel disease. Br. J. Pharmacol. 168 432–444. 10.1111/j.1476-5381.2012.02143.x Tricarico D. Mele A. Calzolaro S. Cannone G. Camerino G. M. Dinardo M. M. (2013). Emerging role of calcium-activated potassium channel in the regulation of cell viability following potassium ions challenge in HEK293 cells and pharmacological modulation. PLoS ONE 8:e69551. 10.1371/journal.pone.0069551 Vecchietti S. Rivolta I. Severi S. Napolitano C. Priori S. G. Cavalcanti C. (2006). Computer simulation of wild-type and mutant human cardiac Na+ current. Med. Biol. Eng. Comput. 44 35–44. 10.1007/s11517-005-0017-x Verkhratsky A. Parpura V. (2014). Store-operated calcium entry in neuroglia. Neurosci Bull. 30 125–133. 10.1007/s12264-013-1343-x Wang X. Li C. Chen Y. Hao Y. Zhou W. Chen C. (2008). Hypoxia enhances CXCR4 expression favoring microglia migration via HIF-1alpha activation. Biochem. Biophys. Res. Commun. 371 283–288. 10.1016/j.bbrc.2008.04.055 Wulff H. Kolski-Andreaco A. Sankaranarayanan A. Sabatier J. M. Shakkottai V. (2007). Modulators of small- and intermediate-conductance calcium-activated potassium channels and their therapeutic indications. Curr. Med. Chem. 14 1437–1457. 10.2174/092986707780831186 Wulff H. Miller M. J. Haensel W. Grissmer S. Cahalan M. D. Chandy K. G. (2000). Design of a potent and selective inhibitor of the intermediate-conductance Ca2+-activated K+ channel, IKCa1: a potential immunosuppressant. Proc. Natl. Acad. Sci. U.S.A. 97 8151–8156. 10.1073/pnas.97.14.8151

http://maxchelator.stanford.edu/CaEGTA-TS.htm